Approval of First HPV Test for Use With SurePath Preservative Fluid

Share this content:
Approval of First HPV Test for Use With SurePath Preservative Fluid
Approval of First HPV Test for Use With SurePath Preservative Fluid

MONDAY, July 11, 2016 (HealthDay News) -- The U.S. Food and Drug Administration has approved Roche's cobas HPV Test as the first diagnostic to be used with cervical cells obtained for a Pap test and collected in SurePath Preservative Fluid.

"Health care providers have been using samples stored in the SurePath Preservative Fluid with human papillomavirus (HPV) tests for some time now, but there have been concerns about false negative results," Alberto Gutierrez, Ph.D., director of the Office of In Vitro Diagnostics and Radiological Health in the FDA's Center for Devices and Radiological Health, said in a news release. "Now health care providers have access to an FDA-approved test and the information they need to use it properly to ensure the most accurate results for their patients."

The agency notes that the test is approved for use in screening women age 30 and older for HPV in order to determine whether additional care is needed. It is also approved for use in women age 21 and older with borderline cellular cytology in order to determine whether additional follow-up and diagnostic procedures are needed. The test is not approved as a first-line primary HPV screening test, and the agency states that health care professionals should use the results in combination with other information, such as patient screening history and risk factors.

The approval is based on a clinical study of 952 eligible women 21 years and older with abnormal Pap test results. The FDA said that the Roche cobas HPV Test with SurePath Preservative Fluid demonstrated similar clinical performance when compared to a previously approved cervical sample type.

The Roche cobas HPV Test is manufactured by Roche Molecular Systems. SurePath Preservative Fluid is manufactured by Becton Dickinson and Company.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters


More in Home

AAN: Erenumab Shows Promise for Hard-to-Treat Migraine

AAN: Erenumab Shows Promise for Hard-to-Treat Migraine

Higher proportion of patients achieved a ≥50 percent reduction in mean monthly migraine days

AAN: New Drug May Help Infants With Spinal Muscular Atrophy

AAN: New Drug May Help Infants With Spinal ...

RG7916 increases survival motor neuron protein level, with 6.5-fold increase noted with highest dose

Small Link for Cannabis Use, Reduced Cognitive Functioning

Small Link for Cannabis Use, Reduced Cognitive Functioning

Small overall effect size for frequent and heavy cannabis use among adolescents, young adults

is free, fast, and customized just for you!

Already a member?

Sign In Now »